# Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

> **NCT02096042** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** 5-Azacytidine

## Key facts

- **NCT ID:** NCT02096042
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096042, "Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02096042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*